Phase II Study of Pembrolizumab, Bevacizumab, and Cyclophosphamide for High-Grade Ovarian Cancer
This study is looking at a combination of three drugs for women with high-grade ovarian cancer who still have a small amount of cancer remaining after their initial treatment. The drugs are pembrolizumab (an immunotherapy that helps your immune system fight cancer), bevacizumab (which targets blood vessel growth in tumors), and oral cyclophosphamide. Researchers want to see if this combination can help control the cancer for at least six months and how safe it is. You may be eligible if you are an adult woman (18 or older) with this type of ovarian cancer and meet other health criteria. The study is currently unclear on its recruitment status and plans to enroll 20 participants.
- Study design
- This is a Phase II interventional study, meaning all participants will receive the study treatment. It aims to enroll 20 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your safety will be monitored throughout the study, which is expected to last an average of one year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy
At a glance
Conditions
Where it's being run
2 sites across 2 statesStudy leadership
- Amir Jazaeri, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0Through study completion; an average of 1 year.